Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI377 plus corticosteroids in acute graft-versus-host disease
CTR20192610Phase 2Terminated
- Sponsor
- Innovent Biologics
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI377 in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Innovent Biologics. Started Jan 2020; status: terminated.
02
Drugs
IBI377
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on CTR20192610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192610.